Corteva Valuation
Is CTVA * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CTVA * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CTVA * (MX$920.22) is trading above our estimate of fair value (MX$857.56)
Significantly Below Fair Value: CTVA * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CTVA *?
Other financial metrics that can be useful for relative valuation.
What is CTVA *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$35.67b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.3x |
Enterprise Value/EBITDA | 12.9x |
PEG Ratio | 2.2x |
Price to Earnings Ratio vs Peers
How does CTVA *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 33.9x | ||
GMEXICO B Grupo México. de | 12.2x | 7.2% | Mex$731.9b |
CEMEX CPO CEMEX. de | 44.2x | 32.3% | Mex$176.6b |
NTR Nutrien | 30x | 16.3% | CA$34.8b |
PE&OLES * Industrias Peñoles. de | 49.4x | n/a | Mex$95.3b |
CTVA * Corteva | 51.1x | 22.9% | Mex$35.7b |
Price-To-Earnings vs Peers: CTVA * is expensive based on its Price-To-Earnings Ratio (51.1x) compared to the peer average (33.9x).
Price to Earnings Ratio vs Industry
How does CTVA *'s PE Ratio compare vs other companies in the Global Chemicals Industry?
Price-To-Earnings vs Industry: CTVA * is expensive based on its Price-To-Earnings Ratio (51.1x) compared to the Global Chemicals industry average (21.8x).
Price to Earnings Ratio vs Fair Ratio
What is CTVA *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 51.1x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CTVA *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$920.22 | Mex$1,175.38 +27.7% | 6.8% | Mex$1,292.71 | Mex$997.23 | n/a | 20 |
Jun ’25 | Mex$920.22 | Mex$1,079.81 +17.3% | 6.8% | Mex$1,187.60 | Mex$916.15 | n/a | 20 |
May ’25 | n/a | Mex$1,068.79 0% | 7.5% | Mex$1,198.88 | Mex$907.72 | n/a | 23 |
Apr ’25 | Mex$935.00 | Mex$1,025.86 +9.7% | 7.7% | Mex$1,163.69 | Mex$881.08 | n/a | 23 |
Mar ’25 | Mex$913.49 | Mex$1,050.80 +15.0% | 7.4% | Mex$1,193.36 | Mex$903.54 | n/a | 24 |
Feb ’25 | Mex$790.00 | Mex$1,011.16 +28.0% | 9.9% | Mex$1,196.06 | Mex$854.33 | n/a | 24 |
Jan ’25 | n/a | Mex$1,010.65 0% | 9.6% | Mex$1,230.08 | Mex$856.60 | n/a | 24 |
Dec ’24 | n/a | Mex$1,010.65 0% | 9.6% | Mex$1,230.08 | Mex$856.60 | n/a | 24 |
Nov ’24 | n/a | Mex$1,186.00 0% | 10.7% | Mex$1,480.39 | Mex$956.84 | n/a | 23 |
Oct ’24 | n/a | Mex$1,198.74 0% | 8.2% | Mex$1,426.99 | Mex$991.93 | n/a | 22 |
Sep ’24 | n/a | Mex$1,176.23 0% | 8.3% | Mex$1,397.56 | Mex$971.47 | n/a | 22 |
Aug ’24 | n/a | Mex$1,175.30 0% | 8.3% | Mex$1,379.95 | Mex$959.24 | n/a | 23 |
Jul ’24 | n/a | Mex$1,220.87 0% | 7.2% | Mex$1,400.33 | Mex$1,041.71 | n/a | 23 |
Jun ’24 | n/a | Mex$1,263.29 0% | 7.8% | Mex$1,527.15 | Mex$1,070.76 | Mex$920.22 | 22 |
May ’24 | n/a | Mex$1,312.50 0% | 8.1% | Mex$1,566.46 | Mex$1,080.32 | n/a | 21 |
Apr ’24 | Mex$1,065.33 | Mex$1,384.30 +29.9% | 7.8% | Mex$1,647.85 | Mex$1,136.45 | Mex$935.00 | 21 |
Mar ’24 | Mex$1,130.72 | Mex$1,380.17 +22.1% | 8.1% | Mex$1,647.55 | Mex$1,136.24 | Mex$913.49 | 21 |
Feb ’24 | Mex$1,200.00 | Mex$1,374.87 +14.6% | 7.7% | Mex$1,635.88 | Mex$1,165.80 | Mex$790.00 | 21 |
Jan ’24 | Mex$1,175.00 | Mex$1,415.84 +20.5% | 7.8% | Mex$1,701.95 | Mex$1,212.88 | n/a | 20 |
Dec ’23 | Mex$1,280.00 | Mex$1,390.22 +8.6% | 8.0% | Mex$1,666.55 | Mex$1,187.65 | n/a | 20 |
Nov ’23 | n/a | Mex$1,405.74 0% | 6.8% | Mex$1,604.27 | Mex$1,223.26 | n/a | 20 |
Oct ’23 | Mex$1,175.00 | Mex$1,379.21 +17.4% | 7.9% | Mex$1,595.73 | Mex$1,115.01 | n/a | 20 |
Sep ’23 | Mex$1,223.88 | Mex$1,340.28 +9.5% | 7.1% | Mex$1,490.43 | Mex$1,125.88 | n/a | 20 |
Aug ’23 | n/a | Mex$1,289.19 0% | 9.5% | Mex$1,467.66 | Mex$1,019.21 | n/a | 20 |
Jul ’23 | Mex$1,109.00 | Mex$1,285.26 +15.9% | 9.6% | Mex$1,449.69 | Mex$1,006.73 | n/a | 18 |
Jun ’23 | Mex$1,219.50 | Mex$1,251.17 +2.6% | 10.4% | Mex$1,418.65 | Mex$985.18 | n/a | 18 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.